The EINSTEIN DVT study
To evaluate whether rivaroxaban is at least as effective as enoxaparin/VKA (VKA: either warfarin or acenocoumarol) in the treatment of subjects with acute symptomatic deep vein thrombosis without symptomatic pulmonary embolism for the prevention of recurrent venous thromboembolic events.
The principal safety objective was the evaluation of major and clinically relevant non-major bleeding events.
- Confirmed acute symptomatic proximal DVT without symptomatic PE
No Exclusion Criteria Available